Please login to the form below

Not currently logged in
Email:
Password:

AZ's Q3 income up as sales stay flat

AstraZeneca's total net income jumped from $1.83bn to $3.13bn in the pharmaceutical company's financial results for the third quarter of 2011, despite sales falling by 2 per cent

AstraZeneca's (AZ) total net income jumped from $1.83bn to $3.13bn in the pharmaceutical company's financial results for the third quarter of 2011.

The increase was largely due to a growth in reporting operating profit of 78 per cent, including $1.48bn from the sale of its Sweden-based dental and devices business Astra Tech to Dentsply.

AZ's total revenue for the period was $8.21bn, a decrease of 2 per cent at constant exchange rates from 2010.

The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort (budesonide/formoterol) for respiratory disorders.

Products affected by generic competition included heartburn treatment Nexium (esomeprazole), with sales falling by 16 per cent in the US and 50 per cent in Western Europe.

Breast cancer therapy Arimidex (anastrozole) was also hit hard, with US sales falling by 81 per cent and Western European sales down by 65 per cent.

Regionally, Western Europe was the worst affected area overall, with revenue down by 15 per cent. US revenue remained level, while, in emerging markets, it grew 7 per cent.

David Brennan, CEO, said: "We have delivered a third quarter revenue and core earnings performance in line with our expectations, against the backdrop of anticipated generic competition and government price interventions."

27th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics